商业保险政策对静脉消融结局的影响
本研究回顾性单中心分析253例患者341条腿的静脉消融,比较五家主要保险公司的政策标准与临床成功、技术成功及并发症的关系。结果显示不同保险政策与静脉消融结局无显著相关,但各政策对可能拒绝承保的比例差异显著,从Connecticut Care的5.6%到UnitedHealthcare的64.1%(P < .0001)。
要点
- 静脉消融的临床成功率为84.2%,技术成功率为95.1%,并发症率为5.6%。
- 在五家保险政策标准内治疗,手术成功、技术成功、并发症率或生活质量改善均无显著差异。
- 临床成功亚组分析显示,不同保险政策可能拒绝承保的比例差异显著,从5.6%到64.1%(P < .0001)。
核心结论
- 不同保险政策与静脉消融结局无相关性。
- 标准更严格的政策通常将治疗限制于较大的静脉,并拒绝相当数量可从治疗中获益的慢性静脉功能不全患者的手术。
研究设计与样本
- 回顾性单中心研究,纳入253例患者共341条接受静脉消融治疗的腿。
- 记录人口学、合并症、症状及临床-病因-解剖-病理生理(CEAP)分类。
- 临床成功定义为随访时患者报告治疗腿症状改善或缓解,技术成功定义为超声示静脉闭合。
- 通过电话调查以0至10数字评分量表询问每条腿治疗前后症状强度及生活质量影响。
- 回顾Aetna、Cigna、Anthem Blue Cross Blue Shield、UnitedHealthcare和Connecticut Care五家保险公司的政策,比较在各政策标准内治疗时的临床和技术成功率。
主要发现
- 患者平均年龄58.5 ± 15.2岁,女性占68%。
- 最常见症状为疼痛(89.7%),47.8%的患者为C3疾病。
- 临床成功率84.2%,技术成功率95.1%,并发症率5.6%。
- 调查显示,术后84.3%的治疗腿数字评分量表评分改善,平均随访26.8个月后76.7%持续改善;76.5%的患者生活质量改善。
- 在五家保险政策标准内治疗时,手术成功、技术成功、并发症率或生活质量改善均无显著差异;多变量分析显示无单一政策与临床成功显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The use of venous ablation (VA) for treatment of chronic venous insufficiency has exponentially increased. To limit cost and overuse, insurance companies have adopted aleatory policies. The goal of this study was to compare the policies of five major local insurance carriers and to determine whether treatment within the criteria of a certain policy is associated with improved patient outcomes. METHODS: A retrospective single-center review of patients treated with VA was performed. Demographics, comorbidities, symptoms, and clinical class (Clinical, Etiology, Anatomy, and Pathophysiology classification) were recorded. Clinical success was defined on chart review by the patients' reporting of improvement or resolution of symptoms in the leg treated on follow-up, and technical success was defined by vein closure on ultrasound. Patients underwent a telephone survey inquiring about intensity of symptoms on a numeric rating scale of 0 to 10 before and after treatment of each leg as well as effects on quality of life (QOL). The policies of Aetna, Cigna, Anthem Blue Cross Blue Shield, UnitedHealthcare, and Connecticut Care were reviewed. The clinical and technical success rates were compared when veins were treated within the criteria of each policy. A subgroup analysis looking at patients who had clinical success only was performed to determine the potential rate of denial of coverage for each policy. A multivariable analysis was performed to determine independent predictors of clinical success. RESULTS: There were 253 patients with 341 legs treated. The mean age was 58.5 ± 15.2 years (68% women). The most common symptom was pain (89.7%), with 47.8% of patients having C3 disease. The clinical success, technical success, and complication rates were 84.2%, 95.1%, and 5.6%, respectively. On survey, there was improvement of the numeric rating scale score in 84.3% of legs treated after the procedure, and 76.7% continued to experience improvement after a mean follow-up of 26.8 months. There was improvement of QOL in 76.5% of patients. There was no significant difference in procedural success, technical success, complication rate, or improvement in QOL when patients were treated within any of the five insurance policies. On multivariable analysis, there was no single policy significantly associated with clinical success. However, subgroup analysis of procedures with clinical success (n = 287) showed a significant difference between the five policies on analysis of the potential denial of coverage, ranging from 5.6% for Connecticut Care to 64.1% for UnitedHealthcare (P < .0001). CONCLUSIONS: The different insurance policies have no correlation with outcomes of VA. Policies with more stringent criteria typically restrict treatment to larger veins and deny procedures to a significant number of patients with chronic venous insufficiency who can benefit from them.
引用
- Ochoa Chaar CI, Aurshina A, Zhang Y, et al. The effect of commercial insurance policies on outcomes of venous ablation. J Vasc Surg Venous Lymphat Disord. 2018. PMID: 29661363. doi:10.1016/j.jvsv.2017.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。